ReGen's zolpidem non-sedating in antidormancy trial

2 September 2007

UK-based biotechnology firm ReGen Therapeutics says that data from a study of its novel formulation of zolpidem indicate that the drug is non-sedating. The firm explained that the assessment had been designed to examine the antidormancy effects of the drug in conscious, fully-perceptive ambulant patients who have various disabilities as a result of brain damage.

The drug, which is an off-patent sedative that was formally marketed by French drug major Sanofi-Aventis under the brand names Stilnox and Ambien (Marketletters passim), was examined in a Phase II placebo-controlled study at sites in the UK and South Africa, where its antidormancy effect was first identified.

The results showed that the 2.5mg dosage, delivered in the form of a sublingual spray, was no more sedating than placebo, while the 5mg and 10mg formulations were sedative in a dose dependant manner. The trial also demonstrated that the spray version of the product had a faster onset of action than tablet versions of the drug.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight